ATMI, Inc. (Nasdaq:ATMI) today launched a disposable bioreactor
representing a new, highly scalable entry point in its line of
mixing and process manufacturing systems for the biopharma and
biotech industries. The introduction took place at INTERPHEX, an
annual conference on life sciences manufacturing equipment,
production process, and packaging developments.
The Integrity™ PadReactor™ system accommodates volumes ranging
from 20 liters to 1,000 liters. The bioreactor is portable along
its entire range of volumes and provides features available on
larger, stationary units while offering much swifter set-up times,
minimal facility requirements, and the economic benefits of
single-use technologies over stainless steel systems.
"When customers see this system for the first time, they're
surprised by the square tank or the sparger's action in the
vessel," said Jeff Craig, ATMI LifeSciences' Global Director of
Marketing and Business Development. "Once they put the PadReactor
to use, we consistently hear them talk about its higher cell
densities in suspension, higher cell viability on microcarriers,
and better overall yields than other single-use bioreactors."
Incorporating key elements of ATMI's industry-leading PadMixer™
technology, the PadReactor system provides enhanced gas exchange,
due to its moving sparger. It also achieves low shear mixing due to
the vertices of the square tank, which act as natural baffles.
These advantages, plus the system's scalability, make it ideal for
the production of vaccines, monoclonal antibodies, and other
secreted proteins.
Rapid Setup
Installation of the PadReactor system can be completed in well
under an hour. The system is fully compatible with ATMI's line of
single-use mixing, media, storage, and bioreactor vessels made from
the Integrity TK8 film polymer. These single-use products are
animal-derived component free (ADCF), integrity tested, and gamma
irradiated. Once a manufacturer qualifies the multi-layer film for
use in a process, requalification is not necessary when introducing
new vessels or different vessel sizes. Certificates of sterility
and film characterization provided with each Integrity TK8 product
can be referenced or included in a customer's batch records.
"TK8 is the same film available in our single-use technologies
across the board, so now you can have a process with integrated
ATMI units of operation from media formulation to bioreactor to
harvest, clarification, and concentration -- even to buffer
preparation to column collection and final formulation," Craig
said. "If you modify or scale your process with any of our
technologies, there are no film requalification issues because it's
always exactly the same film."
Providing customers with bioreactor drive units that can operate
at a range of volumes contributes to savings by eliminating or
reducing the need for capital investment in additional equipment.
Designed to be set up easily with a minimum of commissioning time,
the Integrity PadReactor system has a footprint of 1.3 m x 0.9 m
(1.17 m2 or about 1.4 yd2) at its 25-250
liter volume. At 500-1,000 liters, the system occupies 1.6 m x 1.5
m (2.4 m2 or about 2.87 yd2). Along with the
reduced cycle time, lower operations cost and lower validation cost
of single-use products, the system features detachable drive
hardware that adds to its flexibility and mobility.
"In many settings, mobility is very important," he added. "If
needed, you can literally move the bioreactor vessel to the next
station for harvest, or any other required step."
Open Architecture
Increasing the overall versatility of the Integrity PadReactor
system is ATMI's decision to publish its interface standards,
enabling this single-use bioreactor to be paired with any
controller technology. ATMI can configure the system with
integrated control and monitoring technology or, thanks to its open
architecture, allow users to purchase it in "plug-and-play" mode:
ready for their own choice in technology.
"Users can capitalize on the PadReactor's benefits while putting
their existing or preferred control systems to use," Craig said.
"It makes for an economic and efficient way to introduce the system
to their site. They can continue to rely on their own technology
and expertise to control the process and capture data without any
new training or needing to transition from before."
The single-use Integrity PadReactor system from ATMI
LifeSciences is available for order now. Prices start at under
$30,000 for an open architecture model in which customers supply
their own controller technology. It also can be ordered equipped
with controller technology specified by the customer; pricing for
these configurations will vary.
The PadReactor system can be seen in Booth 1719 at INTERPHEX
2010 at the Jacob K. Javits Convention Center in New York, April
20-22.
About ATMI LifeSciences
ATMI LifeSciences is a leader in single-use mixing, storage, and
bioreactor technology, fluoropolymer-based products, and
custom-engineered, flexible packaging solutions. The business's
fundamental knowledge of polymers, specially selected resins, and
its clean room manufacturing experience coalesce to help drive
optimum performance in critical disposable process operations. For
more information, please visit www.atmi-lifesciences.com.
About ATMI
ATMI, Inc. provides specialty semiconductor materials, and
high-purity materials handling and delivery solutions designed to
increase process efficiencies for the worldwide semiconductor, flat
panel, and life sciences industries. For more information, please
visit http://www.atmi.com.
The ATMI, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5254
ATMI, the ATMI logo, ATMI LifeSciences, Integrity,
PadMixer, and PadReactor are trademarks or registered trademarks of
Advanced Technology Materials, Inc., in the United States, other
countries or both.
Statements contained herein that relate to ATMI's future
performance, including, without limitation, statements with respect
to ATMI's anticipated results of operations or level of business
for 2010 or any other future period, are forward-looking statements
within the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such statements are based on current
expectations only and are subject to certain risks, uncertainties,
and assumptions, including, but not limited to, changes in
semiconductor industry growth (including, without limitation, wafer
starts) or ATMI's markets; competition, problems, or delays
developing, commercializing and delivering new products; problems
or delays in integrating acquired operations and businesses;
uncertainty in the credit and financial markets; and other factors
described in ATMI's Form 10-K for the year ended December 31, 2008,
and other subsequent filings with the Securities and Exchange
Commission. Such risks and uncertainties may cause actual
results to differ materially from those expressed in our
forward-looking statements. ATMI undertakes no obligation to update
any forward-looking statements.
CONTACT: ATMI, Inc.
Dean Hamilton, Director, ATMI Investor Relations
& Corporate Communications
203.207.9349
203.794.1100 x4202
dhamilton@atmi.com
Atmi Inc. (MM) (NASDAQ:ATMI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Atmi Inc. (MM) (NASDAQ:ATMI)
Historical Stock Chart
From Jul 2023 to Jul 2024